aliskiren vs nirmatrelvir/ritonavir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of aliskiren and nirmatrelvir/ritonavir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Cardiovascular agents aliskiren, ticagrelor, vorapaxar clopidogrel ↑ aliskiren ↑ ticagrelor ↑ vorapaxar ↓ clopidogrel active metabolite Avoid concomitant use with PAXLOVID.
Tekturna
Paxlovid
Tekturna is a medicine used to treat high blood pressure. It helps lower blood pressure, which can reduce the risk of strokes and heart attacks.
Paxlovid is a medicine used to treat mild to moderate COVID-19 in adults. It helps prevent severe illness, hospitalization, or death in people at high risk.
Tekturna is used to treat high blood pressure in adults and children who weigh at least 110 pounds and are 6 years or older. Lowering your blood pressure helps prevent strokes and heart attacks. It is important to manage high blood pressure with a healthy lifestyle too.
Paxlovid treats mild to moderate COVID-19 in adults. You must be at high risk of your illness becoming severe. This includes needing to go to the hospital or possibly dying from COVID-19. Paxlovid is not for preventing COVID-19 before or after exposure.
Tekturna works by blocking a substance in your body called renin. Renin helps to control your blood pressure. By blocking renin, Tekturna helps to lower your blood pressure.
Paxlovid contains two medicines, nirmatrelvir and ritonavir. Nirmatrelvir stops the virus from multiplying in your body. Ritonavir helps nirmatrelvir stay in your body longer so it can work better.
- • Diarrhea
- • Change in taste
- • Diarrhea
- Asthenia 367
- Fall 356
- Nausea 336
- Dyspnoea 315
- Headache 301
- COVID-19 22,774
- COVID-19 coming back 20,089
- Change in taste 7,316
- Diarrhea 4,003
- Feeling sick to your stomach 2,620
Tekturna can harm your unborn baby, even causing death. If you become pregnant, stop taking Tekturna right away and tell your doctor.
Paxlovid can interact with many other medicines, causing serious or life-threatening problems. Before taking Paxlovid, tell your doctor about all the medicines you take. Your doctor may need to adjust the dose of your other medicines or monitor you more closely.
Tekturna can cause serious harm or death to an unborn baby. If you are pregnant or plan to become pregnant, talk to your doctor about other blood pressure medicines. Breastfeeding is not recommended while taking Tekturna.
There is not enough information about nirmatrelvir's safety during pregnancy. Studies on ritonavir in pregnant women have not shown an increased risk of birth defects. Talk to your doctor about the risks and benefits of taking Paxlovid if you are pregnant or breastfeeding.
How to Read This aliskiren vs nirmatrelvir/ritonavir Comparison
aliskiren is classified in the Direct Renin Inhibitor drug class, while nirmatrelvir/ritonavir sits within the Antiviral (Protease Inhibitor Combination) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aliskiren has 1,675 submissions while nirmatrelvir/ritonavir has 56,802. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to this combination stops your body from breaking down aliskiren properly, leading to much higher amounts of the drug in your system.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aliskiren or nirmatrelvir/ritonavir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.